4599.T
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of innovative drug therapies.
Business. 4599.T is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Detailed information regarding its operating segments, headquarters location, and primary stock exchange listing is not available in the provided data. Consequently, the company is described at the industry level without specific geographic or segmental breakdowns.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4599.T is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Detailed information regarding its operating segments, headquarters location, and primary stock exchange listing is not available in the provided data. Consequently, the company is described at the industry level without specific geographic or segmental breakdowns.
The company maintains a strong liquidity position, with a current ratio of 83.35, indicating a significant excess of current assets over current liabilities. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce the company's financial stability. However, the company's operating cash flow is negative at -1.41 billion JPY, and free cash flow is also negative at -1.92 billion JPY, suggesting ongoing operational challenges.
Profitability metrics are negative, with a return on equity of -26.38% and a return on assets of -25.66%, both significantly below industry norms. The company reported a net loss of 1.93 billion JPY, and operating income was also negative at 1.93 billion JPY, indicating a lack of profitability. The price-to-book ratio of 2.47 suggests that the market is valuing the company at a premium to its book value, despite the negative earnings.
The company's revenue is reported as 0.0 JPY, which may indicate a reporting anomaly or a strategic shift in operations. There is no disclosed segment or geographic breakdown provided in the available data, making it difficult to assess revenue concentration or diversification. The absence of detailed segment data limits the ability to evaluate the company's exposure to different markets or product lines.
The company's growth trajectory is unclear due to the lack of historical revenue data and the absence of forward-looking guidance in the provided information. Analysts have assigned a mean price target of 700.00 JPY, significantly higher than the current market price of 288.0 JPY, suggesting a potential for substantial upside. However, the mean recommendation of 2.00 (Buy) is tempered by the absence of strong-buy ratings and the presence of only one buy recommendation.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is free of long-term debt, and the dilution potential is low, as the basic and diluted shares outstanding are identical. However, the negative operating and free cash flows suggest potential liquidity pressures in the future.
Recent events and filings do not provide specific details on the company's operations or strategic direction. The absence of detailed transcripts or recent filings limits the ability to assess the company's management commentary or strategic initiatives. The company's capital expenditure of -43.86 million JPY indicates a reduction in investment in physical assets.
- The company has a strong liquidity position with a current ratio of 83.35 and no long-term debt.
- Profitability is negative, with a return on equity of -26.38% and a return on assets of -25.66%.
- Analysts have assigned a mean price target of 700.00 JPY, significantly higher than the current market price of 288.0 JPY.
- The company's capital structure is free of long-term debt, and the dilution potential is low.
- The absence of detailed segment and geographic data limits the ability to assess revenue concentration and diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- 4599.T Market data — financials · 2026-05-26
- StemRIM Inc Market data — analyst estimates · 2026-05-26